Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Status of Cellular Therapy in the Asia Pacific Rim” Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASBMT and CIBMTR Tandem Meeting 2019
Avalon Accepted into the American Society for Blood and Marrow Transplantation (ASBMT) Corporate Council
FREEHOLD, N.J., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (NASDAQ listed Avalon GloboCare AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that its President and Chief Executive Officer, David Jin, M.D., Ph.D., will co-chair a session, entitled “Status of Cellular Therapy in the Asia Pacific Rim,” at the Transplantation & Cellular Therapy (TCT) Meetings in Houston, TX. TCT Meetings are the combined annual meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR).
|Date:||Saturday, February 23, 2019|
|Time:||1:45PM - 2:30PM|
|Location:||Hilton Americas Houston - Grand Ballroom G|
|1600 Lamar Street, Houston, Texas|
The session, "Status of Cellular Therapy in the Asia Pacific Rim," will provide a venue to review and examine the current status and future trends in cellular therapy (particularly CAR-T), within Asia and the Pacific Rim region. Faculty for this session will include speakers from China, Japan, and South Korea and will discuss and exchange knowledge on clinical protocols, outcome analysis, regulatory affairs, standardization, and accreditation related to cellular therapy.
Additionally, Avalon GloboCare announces that it has been accepted as a member of the Corporate Council of the American Society for Blood and Marrow Transplantation (ASBMT). Avalon joins a select group of twenty leading biotech companies within the cellular therapy sector, including Novartis, Merck and Co., Amgen, Gilead/Kite, Bristol-Myers Squibb/Celgene, Sanofi Genzyme, Takeda Oncology and others.
Council members meet with ASBMT Board Members and Past-Presidents to discuss critical BMT and cellular therapy issues of mutual concern, find solutions to pressing challenges, share knowledge on best practices and advise ASBMT on its major initiatives. By pooling their resources and expertise, Council members and the ASBMT Board can engage in joint problem-solving and collaborative opportunities that will advance the cause and culture of blood and marrow transplantation and cellular therapy.
“We are honored to lead this panel discussion at the industry renowned TCT Meetings, comprising the leading experts in an evolving cellular therapy ecosystem. We look forward to leveraging our respective experience and capabilities in cell-based technologies and therapeutics. We are also honored to join the ASBMT’s Corporate Council in order to collaborate alongside many of the world’s largest biotech companies. We will contribute our scientific, regulatory, clinical and commercial expertise to help empower high impact, transformative cell-based technologies and their clinical applications,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to advancing cell-based technologies and therapeutics, with a focus on developing and empowering innovative and transformative cell-based technologies and their clinical applications. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
Crescendo Communications, LLC
Tel: (212) 671-1020
Released February 4, 2019